Skip to main content
Crinetics Pharmaceuticals, Inc. logo

Crinetics Pharmaceuticals, Inc. — Investor Relations & Filings

Ticker · CRNX ISIN · US22663K1079 LEI · 549300Q1CNFXK5P31D28 US Manufacturing
Open in API
Filings indexed 640 across all filing types
Latest filing 2026-03-23 Board/Management Inform…
Country US United States of America
Listing US CRNX

About Crinetics Pharmaceuticals, Inc.

https://www.crinetics.com/

Crinetics Pharmaceuticals, Inc. is a pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors. The company leverages its expertise in G-protein coupled receptors (GPCRs) to develop orally administered therapies aimed at addressing unmet medical needs. Its lead product candidate is paltusotine, an oral, nonpeptide somatostatin receptor type 2 (SST2) agonist for the treatment of acromegaly and carcinoid syndrome. The company's pipeline also includes atumelnant, an oral ACTH antagonist for conditions of excess cortisol such as congenital adrenal hyperplasia and Cushing's disease. Crinetics aims to build a leading endocrinology company by pioneering treatments that offer patients better disease control and greater convenience.

Recent filings

Filing Released Lang Actions
8-K - Crinetics Pharmaceuticals, Inc. (0001658247) (Filer)
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The key content is the resignation of a Chief Development and Operating Officer, which is a change in senior management. The document does not contain financial data or detailed reports but announces a management change. According to the filing definitions, announcements of changes in the company's board of directors or senior management fall under Board/Management Information (MANG). The document length is 3521 characters, which is consistent with a brief announcement rather than a full report. Therefore, the correct classification is MANG with high confidence.
2026-03-23 English
4 - CRINETICS PHARMACEUTICALS, INC. (0001658247) (Filer)
Director's Dealing
2026-03-04 English
4 - CRINETICS PHARMACEUTICALS, INC. (0001658247) (Filer)
Director's Dealing
2026-03-04 English
8-K - CRINETICS PHARMACEUTICALS, INC. (0001658247) (Filer)
Audit Report / Information Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated February 27, 2026. It announces the dismissal of the previous independent registered public accounting firm (BDO USA, P.C.) and the appointment of a new one (PricewaterhouseCoopers LLP). It includes details about the audit reports for fiscal years ended December 31, 2025 and 2024, and mentions no disagreements or reportable events. The document also references a letter from the former auditor attached as an exhibit. This type of filing is specifically about changes in the company's auditor and related audit information, which fits the category of Audit Report / Information (AR). The document is not a full annual report or audit report itself but a current report about audit firm changes and related disclosures, which is typical for AR filings. The length and content confirm it is not a mere announcement or certification but a substantive regulatory filing about audit changes.
2026-03-03 English
10-K - CRINETICS PHARMACEUTICALS, INC. (0001658247) (Filer)
Annual Report FY 2025
2026-02-26 English
8-K - CRINETICS PHARMACEUTICALS, INC. (0001658247) (Filer)
Regulatory Filings Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated February 26, 2026, reporting financial results for the period ended December 31, 2025. It includes a press release as Exhibit 99.1 with the financial results. The text states that the press release is attached and incorporated by reference but does not contain the full financial statements or detailed financial data itself. The document length is 4032 characters, which is relatively short and consistent with a report publication or announcement rather than a full financial report. According to the 'Menu vs Meal' rule, since this document is primarily an announcement of the financial results press release and does not contain substantive financial data or analysis, it should be classified as a Regulatory Filing (RNS), which is the fallback category for such filings that do not fit other specific categories.
2026-02-26 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.